1029691-06-2

Basic information

• Product Name: 1H-Isoindole-1,3(2H)-dione, 2-(3-oxocyclopentyl)-
• Synonyms: 1H-Isoindole-1,3(2H)-dione, 2-(3-oxocyclopentyl)-;2-(3-oxocyclopentyl)-1H-Isoindole-1,3(2H)-dione;2-(3-Oxocyclopentyl)isoindoline-1,3-dione
• CAS NO: 1029691-06-2
• Molecular Formula: C₁₃H₁₁NO₃
• Molecular Weight: 229.23134
• Mol File: 1029691-06-2.mol

Chemical Properties

• Boiling Point: 393.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.419±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -2.33±0.20(Predicted)
• CAS DataBase Reference: 1H-Isoindole-1,3(2H)-dione, 2-(3-oxocyclopentyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindole-1,3(2H)-dione, 2-(3-oxocyclopentyl)-(1029691-06-2)
• EPA Substance Registry System: 1H-Isoindole-1,3(2H)-dione, 2-(3-oxocyclopentyl)-(1029691-06-2)

Safety Data

• Hazardous Substances Data: 1029691-06-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Isoindole-1,3(2H)-dione, 2-(3-oxocyclopentyl)is used as a building block in organic synthesis for the preparation of novel compounds. Its unique cyclic structure and functional groups contribute to the creation of new chemical entities with potential applications in various fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1H-Isoindole-1,3(2H)-dione, 2-(3-oxocyclopentyl)is utilized for the development of compounds with potential biological activities. Its structural features make it a valuable component in the design and synthesis of new pharmaceutical agents.
Used in Pharmaceutical Industry:
1H-Isoindole-1,3(2H)-dione, 2-(3-oxocyclopentyl)is used as a key intermediate in the synthesis of pharmaceuticals. Its unique structure and functional groups can be leveraged to create new drugs with improved therapeutic properties.
Used in Research and Development:
This chemical compound is used in research and development for exploring its potential applications and properties. Further investigation is necessary to understand its full potential and to develop new methods for its synthesis and utilization.

Upstream product

• 136918-14-4 phthalimide 
• 930-30-3 cyclopent-2-enone 

Downstream Products

• 1196037-86-1 C₂₉H₃₆FN₃O₃Si 
• 1196037-70-3 (S)-7-cyano-4-(3-fluoro-2-methoxybenzyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-2-ylcarbamic acid isopropyl ester 
• 1196037-83-8 (S)-7-cyano-4-(3-fluoro-2-hydroxybenzyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-2-ylcarbamic acid isopropyl ester 
• 1196037-85-0 [(S)-7-cyano-4-(5-fluoro-2-hydroxybenzyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-2-yl]carbamic acid isopropyl ester 
• 1196037-71-4 [(S)-7-cyano-4-(2-methoxybenzyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-2-yl]carbamic acid isopropyl ester 
• 1196037-84-9 [(S)-7-cyano-4-(2-hydroxybenzyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-2-yl]carbamic acid isopropyl ester 
• 1029691-17-5 (±)-(7-cyano-1,2,3,4-tetrahydrocyclopenta[b]indol-2-yl)carbamic acid tert-butyl ester 
• 1445791-53-6 C₁₈H₁₇ClF₂N₂O₄S 
• 1184919-69-4 rac-3-aminocyclopentanol hydrochloride 
• 1445796-28-0 C₁₃H₁₇NO₃ 
• 1401075-42-0 3-amino-1-phenylcyclopentanol 
• 1401075-40-8 2-(3-hydroxy-3-phenylcyclopentyl)isoindoline-1,3-dione 
• 1307213-00-8 [(S)-7-cyano-4-((2R,3S)-3-hydroxytetrahydrofuran-2-ylmethyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-2-yl]-carbamic acid isopropyl ester 
• 1307213-09-7 (S)-7-bromo-1,2,3,4-tetrahydro-cyclopenta[b]indol-2-ylamine (R)-2-hydroxy-3-phenylpropionic acid salt 

Relevant articles and documents

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds of formula (I) that modulate progranulin and methods of using the compounds in progranulin- associated disorders, such as Frontotemperal lobe dementia (FTLD).

PHOSPHONATE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

MULTIVALENT RAS BINDING COMPOUNDS

Described herein are compounds that modulate Ras signaling, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with altered Ras signaling. Further described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds and methods of using such compounds in the treatment of cell proliferative disorders, including cancer.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

TRPV1 Antagonists

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X1, X2, X3, X4, J, K, L, X5, X6, Rb, G2, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Androgen Receptor Modulator and Uses Thereof

The present invention relates to the compound of the formula: to pharmaceutical compositions comprising the compound of Formula (I); and to methods for treating or preventing hypogonadism, osteoporosis, osteopenia, sarcopenia, cachexia, muscle atrophy, sexual dysfunction or erectile dysfunction, comprising administering to a patient in need thereof an effective amount of the compound of Formula (I).

TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass or strength, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. X-17142.

TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS

The present invention provides a compound of the Formula (I), or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating or preventing physiological disorders, particularly reduced bone mass, osteoporosis, osteopenia, reduced muscle mass or strength, or erectile dysfunction comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.